Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
The OncLive Insider app is live!
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Immuno-Oncology | Specialty
home
Content Type
Heterogeneity of Metastatic HR+ Breast Cancer
October 2nd 2017
Understanding Abemaciclib: A New CDK4/6 Inhibitor
October 2nd 2017
CDK4/6 Inhibitor Combinations for HR+ mBC
October 2nd 2017
ER+/HER2+ Metastatic Breast Cancer
October 2nd 2017
Future Directions: CDK4/6 Inhibitors in Breast Cancer
October 2nd 2017
Treatment Selection for HR+ mBC
October 2nd 2017
mBC: CDK4/6 Inhibitor Patient Selection/Sequencing
October 2nd 2017
CDK4/6 Inhibitors in Breast Cancer: Ongoing Research
October 2nd 2017
FDA Approval for Abemaciclib
October 2nd 2017
MONARCH 3: Abemaciclib With Endocrine Therapy for mBC
October 2nd 2017
MONARCH 1: Abemaciclib Monotherapy for HR+ mBC
October 2nd 2017
Abemaciclib + Fulvestrant at Progression of HR+ mBC
October 2nd 2017
Abemaciclib for ER+ mBC
October 2nd 2017
CDK4/6 Inhibitors: Managing Toxicity in HR+ mBC
October 2nd 2017
Clinical Experience: CDK4/6 Inhibitors in Breast Cancer
October 2nd 2017
CDK 4/6 Inhibitors in Metastatic Breast Cancer
October 2nd 2017
Future Directions in NSCLC Immuno-Oncology Research
September 28th 2017
Immuno-Oncology Combination Therapy in NSCLC
September 28th 2017
Promising Immunotherapy Agents for NSCLC
September 28th 2017
PACIFIC Trial: Durvalumab for Stage 3 NSCLC
September 28th 2017
NEXT PAGE
<
1
...
97
98
99
100
101
102
103
104
105
...
203
>
PREVIOUS PAGE